DAX24.389 +0,5%ESt505.407 +0,3%Top 10 Crypto16,40 +3,4%Dow44.461 -0,4%Nas21.130 +0,2%Bitcoin103.688 +0,6%Euro1,1449 +0,4%Öl73,11 -0,5%Gold3.311 +1,1%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Novo Nordisk A3EU6F NVIDIA 918422 Heidelberger Druckmaschinen 731400 Rheinmetall 703000 adidas A1EWWW Microsoft 870747 Commerzbank CBK100 Mercedes-Benz Group (ex Daimler) 710000 Siemens Energy ENER6Y DroneShield A2DMAA BYD A0M4W9 Lufthansa 823212 RENK RENK73 Deutsche Bank 514000 Meta Platforms (ex Facebook) A1JWVX
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX mit weiterer Erholung -- Asiens Börsen uneinheitlich -- HENSOLDT wächst weiter kräftig -- BMW mit Gewinneinbruch -- Airbus verdreifacht Gewinn -- DroneShield, Bayer, Microsoft, Meta im Fokus
Top News
Rolls-Royce-Aktie haussiert: Rolls-Royce wird optimistischer für 2025 Rolls-Royce-Aktie haussiert: Rolls-Royce wird optimistischer für 2025
BYD-Aktie fällt nach Aktiensplit in Shenzen weiter zurück - Probleme im Heimatmarkt BYD-Aktie fällt nach Aktiensplit in Shenzen weiter zurück - Probleme im Heimatmarkt
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Ãœbersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Novavax Aktie

Handeln
Novavax Aktien-Sparplan
6,03 EUR +0,07 EUR +1,16 %
FSE
6,96 USD -0,05 USD -0,71 %
nachbörslich
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.968,40 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA2PKMZ

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS6700024010

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolNVAX

Novavax Aktien News

DatumMeistgelesen
PR NewswireNovavax's Nuvaxovid™ Receives Positive CHMP Opinion for Full Marketing Authorization for the Prevention of COVID in the EU
PR NewswireAccess to Novavax's COVID Vaccine Grows with Extended Interim Authorization for Adolescents in Singapore
PR NewswireAccess to Novavax's COVID Vaccine Grows with Extended Interim Authorization for Adolescents in Singapore
PR NewswireNovavax Reports First Quarter 2023 Financial Results and Operational Highlights
PR NewswirePositive Phase 2 Topline Results Show Novavax's COVID-Influenza Combination, Stand-alone Influenza and High-dose COVID Vaccine Candidates Demonstrate Robust Immune Responses
PR NewswirePositive Phase 2 Topline Results Show Novavax's COVID-Influenza Combination, Stand-alone Influenza and High-dose COVID Vaccine Candidates Demonstrate Robust Immune Responses
PR NewswirePositive Phase 2 Topline Results Show Novavax's COVID-Influenza Combination, Stand-alone Influenza and High-dose COVID Vaccine Candidates Demonstrate Robust Immune Responses
PR NewswirePositive Phase 2 Topline Results Show Novavax's COVID-Influenza Combination, Stand-alone Influenza and High-dose COVID Vaccine Candidates Demonstrate Robust Immune Responses
PR NewswireNovavax to Participate in the BofA Securities 2023 Health Care Conference
PR NewswireNovavax to Host Conference Call to Discuss First Quarter 2023 Financial Results and Operational Highlights on May 9, 2023
PR NewswireNovavax Grows Presence at World Vaccine Congress 2023 and 33rd European Congress of Clinical Microbiology & Infectious Diseases
PR NewswireNovavax to Participate in TD Cowen's 43rd Annual Health Care Conference
PR NewswireNovavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4)
PR NewswireNovavax Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
PR NewswireNovavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights on February 28, 2023
PR NewswireU.S. Government and Novavax Extend Partnership, Securing Up to 1.5 Million Additional Doses of Novavax' COVID-19 Vaccine
PR NewswireU.S. Government and Novavax Extend Partnership, Securing Up to 1.5 Million Additional Doses of Novavax' COVID-19 Vaccine
PR NewswireU.S. Government and Novavax Extend Partnership, Securing Up to 1.5 Million Additional Doses of Novavax' COVID-19 Vaccine
PR NewswireU.S. Government and Novavax Extend Partnership, Securing Up to 1.5 Million Additional Doses of Novavax' COVID-19 Vaccine
PR NewswireNovavax Nuvaxovid COVID-19 Vaccine Approved in South Korea as an Adult Booster
PR NewswireNovavax Nuvaxovid COVID-19 Vaccine Approved in South Korea as an Adult Booster
PR NewswireNovavax Names John C. Jacobs as New President & Chief Executive Officer
PR NewswireNovavax Announces Initiation of Phase 2 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates
PR NewswireNovavax Announces Initiation of Phase 2 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates
PR NewswireNovavax to Participate in BofA Securities 2022 Virtual Biotech SMID Cap Conference
PR NewswireWorld Health Organization Updates Emergency Use Listing for Novavax Nuvaxovid COVID-19 Vaccine as a Primary Series in Adolescents and as a Booster in Adults
PR NewswireWorld Health Organization Updates Emergency Use Listing for Novavax Nuvaxovid COVID-19 Vaccine as a Primary Series in Adolescents and as a Booster in Adults
PR NewswireNovavax Nuvaxovid COVID-19 Vaccine Receives Expanded Authorization in Canada as a Booster in Adults
PR NewswireNovavax Nuvaxovid COVID-19 Vaccine Receives Expanded Authorization in Canada as a Booster in Adults
PR NewswireNovavax to Participate in Jefferies London Healthcare Conference
PR NewswireNovavax Nuvaxovid™ COVID-19 Vaccine▼ Authorized in the United Kingdom for Use as a Booster in Adults
PR NewswireNovavax Nuvaxovid™ COVID-19 Vaccine▼ Authorized in the United Kingdom for Use as a Booster in Adults
PR NewswireNovavax Reports Third Quarter 2022 Financial Results and Operational Highlights
PR NewswireNovavax Phase 3 COVID-19 Omicron Trial Supports the Continued and Future Use of Novavax Prototype Vaccine as a Booster
PR NewswireNovavax Phase 3 COVID-19 Omicron Trial Supports the Continued and Future Use of Novavax Prototype Vaccine as a Booster
PR NewswireNovavax Phase 3 COVID-19 Omicron Trial Supports the Continued and Future Use of Novavax Prototype Vaccine as a Booster
PR NewswireNovavax Phase 3 COVID-19 Omicron Trial Supports the Continued and Future Use of Novavax Prototype Vaccine as a Booster
PR NewswireNovavax Appoints Rick Rodgers to Board of Directors
PR NewswireNovavax Appoints Rick Rodgers to Board of Directors
PR NewswireNovavax to Host Conference Call to Discuss Third Quarter 2022 Financial Results and Operational Highlights on November 8, 2022

Novavax News

Novavax News: auf dieser Seite finden Sie alle Novavax News und Nachrichten zur Novavax Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Novavax News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Novavax News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.